Journal
ANNUAL REVIEW OF MEDICINE, VOL 67
Volume 67, Issue -, Pages 165-183Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-051914-021702
Keywords
immunotherapy; adoptive T cell therapy; CD19; CD20; CD30; kappa light chain
Categories
Funding
- NCI NIH HHS [3P50CA126752, P30 CA125123, P01 CA094237, P50 CA126752] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P50CA126752, P01CA094237, P30CA125123] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Lymphomas arise from clonal expansions of B, T, or NK cells at different stages of differentiation. Because they occur in the immunocyte-rich lymphoid tissues, they are easily accessible to antibodies and cell-based immunotherapy. Expressing chimeric antigen receptors (CARs) on T cells is a means of combining the antigen-binding site of a monoclonal antibody with the activating machinery of a T cell, enabling antigen recognition independent of major histocompatibility complex restriction, while retaining the desirable antitumor properties of a T cell. Here, we discuss the basic design of CARs and their potential advantages and disadvantages over other immune therapies for lymphomas. We review current clinical trials in the field and consider strategies to improve the in vivo function and safety of immune cells expressing CARs. The ultimate driver of CAR development and implementation for lymphoma will be the demonstration of their ability to safely and cost-effectively cure these malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available